CERS Insider Trading

Insider Ownership Percentage: 3.40%
Insider Buying (Last 12 Months): $9,675.00
Insider Selling (Last 12 Months): $816,701.40

Cerus Insider Trading History Chart

This chart shows the insider buying and selling history at Cerus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$500k$0$500kTotal Insider BuyingTotal Insider Selling

Cerus Share Price & Price History

Current Price: $1.30
Price Change: +0.30 (1.20%)
As of 04/17/2025 05:00 PM ET

This chart shows the closing price history over time for CERS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$1.30Closing price on 04/17/25:

SEC Filings (Institutional Ownership Changes) for Cerus (NASDAQ:CERS)

78.37% of Cerus stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CERS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$131kbought$37ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M$0$10MTotal InflowsTotal Outflows
Cerus logo
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
Read More on Cerus

Today's Range

Now: $1.30
Low: $1.28
High: $1.32

50 Day Range

MA: $1.50
Low: $1.22
High: $1.86

52 Week Range

Now: $1.30
Low: $1.12
High: $2.54

Volume

1,006,055 shs

Average Volume

1,259,792 shs

Market Capitalization

$241.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7

Who are the company insiders with the largest holdings of Cerus?

Cerus' top insider investors include:
  1. William Mariner Greenman (CEO)
  2. Vivek K Jayaraman (COO)
  3. Kevin Dennis Green (CFO)
  4. Richard J Benjamin (Insider)
  5. Chrystal Jensen (Insider)
  6. Carol Moore (SVP)
  7. Eric Bjerkholt (Director)
  8. Daniel N Swisher Jr (Director)
  9. Ann Lucena (Director)
  10. Hua Shan (Director)
Learn More about top insider investors at Cerus.

Who are the major institutional investors of Cerus?

Cerus' top institutional investors include:
  1. Assenagon Asset Management S.A. — 0.66%
  2. Bouvel Investment Partners LLC — 0.27%
  3. Rhumbline Advisers — 0.14%
  4. Wealth Enhancement Advisory Services LLC — 0.03%
  5. Pallas Capital Advisors LLC — 0.01%
  6. Merit Financial Group LLC — 0.01%
Learn More about top institutional investors of Cerus stock.

Which major investors are selling Cerus stock?

Within the last quarter, CERS stock was sold by these institutional investors:
  1. Assenagon Asset Management S.A.
Within the previous year, company insiders that have sold Cerus company stock include:
  1. William Mariner Greenman (CEO)
  2. Vivek K Jayaraman (COO)
  3. Kevin Dennis Green (CFO)
  4. Richard J Benjamin (Insider)
  5. Chrystal Jensen (Insider)
Learn More investors selling Cerus stock.

Which major investors are buying Cerus stock?

During the previous quarter, CERS stock was bought by institutional investors including:
  1. Wealth Enhancement Advisory Services LLC
  2. Pallas Capital Advisors LLC
  3. Merit Financial Group LLC
  4. Rhumbline Advisers
  5. Bouvel Investment Partners LLC
Within the last year, these company insiders have bought Cerus stock:
  1. William Mariner Greenman (CEO)
  2. Vivek K Jayaraman (COO)
  3. Kevin Dennis Green (CFO)
  4. Richard J Benjamin (Insider)
Learn More investors buying Cerus stock.